Latest News

STAT Plus: Pharmalittle: A new scandal for Novartis; opioid distributors offer to settle lawsuits

Good morning. Elizabeth Cooney here again in Boston, filling in for Ed Silverman while he takes a summer break. As he would no doubt remind us, we’ve made it to the middle of the week, so why not carry on? We have some news to get you going:

Novartis CEO Vas Narasimhan began his tenure with an inherited scandal. Now he’s got one all his own, STAT says. At issue is what Novartis knew — and when it knew — about the manipulation of data used to win approval of its gene therapy for spinal muscular atrophy.

Continue to STAT Plus to read the full story…

Source link

Related posts

Findings validate link between environmental factors, dry eye


Developing a Data Dashboard for Population Health Surveillance: Widening Access to Clinical Trial Findings


ERLEADA®▼(apalutamide) améliore considérablement la survie globale et la survie sans progression radiographique chez les patients atteints d’un cancer de la prostate métastatique hormono-sensible


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy